Join the Nephropathy group to help and get support from people like you.
Nephropathy News
FDA Grants Accelerated Approval for Vanrafia (atrasentan) for Proteinuria Reduction in Primary IgA Nephropathy
Basel, April 3, 2025 – Novartis today announced the US Food and Drug Administration (FDA) has granted accelerated approval for Vanrafia® (atrasentan), a potent and selective endothelin A (ETA) re...
ASN: Atrasentan Significantly and Clinically Meaningfully Cuts Proteinuria
WEDNESDAY, Oct. 30, 2024 – Atrasentan is associated with a significant and clinically meaningful reduction in proteinuria compared with placebo in patients with immunoglobulin A (IgA) nephropathy,...
Calliditas Therapeutics Announces Full FDA Approval of Tarpeyo, the Only FDA-Approved Treatment for IgA Nephropathy to Significantly Reduce the Loss of Kidney Function
December 20, 2023 Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), today announced that the U.S. Food and Drug Administration (FDA) has approved Tarpeyo (budesonide) ...
FDA Approves Tarpeyo (budesonide) to Reduce Proteinuria in IgA Nephropathy
STOCKHOLM, Dec. 15, 2021 /PRNewswire/ – Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the US Food and Drug Administration (FDA) has approved...